Mamber S W, Mitulski J D, Hamelehle K L, French J C, Hokanson G C, Shillis J L, Leopold W R, Von Hoff D D, Tunac J B
J Antibiot (Tokyo). 1987 Jan;40(1):73-6. doi: 10.7164/antibiotics.40.73.
The antibiotic acetomycin was active in vitro against HCT-8 human colon adenocarcinoma cells (IC50, 1.5 microgram/ml) and L1210 murine leukemia cells (IC50, 2.2 micrograms/ml). Acetomycin also had marked activity in the human tumor stem cell assay, with a 33% overall response rate (less than or equal to 30% survival) against 49 primary tumors. However, acetomycin was inactive in four in vivo tumor assay systems (L1210 and P388 leukemias, B16 melanoma and the MX-1 mammary xenograft system). This lack of in vivo activity may result from metabolic inactivation of acetomycin.
抗生素阿西霉素在体外对HCT - 8人结肠腺癌细胞（IC50，1.5微克/毫升）和L1210小鼠白血病细胞（IC50，2.2微克/毫升）具有活性。阿西霉素在人类肿瘤干细胞试验中也具有显著活性，对49个原发性肿瘤的总体反应率为33%（存活率小于或等于30%）。然而，阿西霉素在四种体内肿瘤试验系统（L1210和P388白血病、B16黑色素瘤和MX - 1乳腺异种移植系统）中无活性。这种体内活性的缺乏可能是由于阿西霉素的代谢失活所致。
